Johnson & Johnson announced that the FDA approved its dual energy catheter ablation platform designed to deliver radiofrequency and pulsed field ablation energy via a single catheter.The platform (Dual Energy Thermocool Smarttouch SF Platform) is integrated with the company’s existing mapping, imaging and pulsed field index guidance system (CARTO), and is indicated for the treatment of refractory recurrent symptomatic paroxysmal…
Source: Healio News
